Publicaciones (13) Publicaciones de Dalia Salim Quwaider

2024

  1. Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling

    Haematologica, Vol. 109, Núm. 3, pp. 877-887

2022

  1. Expression of p53 protein isoforms predicts survival in patients with multiple myeloma

    American Journal of Hematology, Vol. 97, Núm. 6, pp. 700-710

  2. RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation

    Experimental Hematology and Oncology, Vol. 11, Núm. 1

2021

  1. Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma

    Cells, Vol. 10, Núm. 3

2020

  1. FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma

    Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 7, pp. 4171-4182

2019

  1. Factors regulating microRNA expression and function in multiple myeloma

    Non-coding RNA, Vol. 5, Núm. 1

2017

  1. DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  2. Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  3. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

2016

  1. Post-transcriptional modifications contribute to the upregulation of cyclin D2 in multiple myeloma

    Clinical Cancer Research, Vol. 22, Núm. 1, pp. 207-217

2015

  1. MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL

    BMC Cancer, Vol. 15, Núm. 1

2014

  1. Preclinical activity of the oral proteasome inhibitor mln9708 in myeloma bone disease

    Clinical Cancer Research, Vol. 20, Núm. 6, pp. 1542-1554

2013

  1. Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication

    Haematologica, Vol. 98, Núm. 4, pp. 640-648